NAT2 polymorphisms significantly impact the metabolism of drugs such as isoniazid, used in tuberculosis treatment, and sulfamethazine, an antibiotic. Slow acetylators may experience higher plasma levels of these drugs, leading to increased toxicity and adverse effects. Conversely, fast acetylators may require higher doses to achieve therapeutic effects, complicating the standardization of treatment protocols.
